Last reviewed · How we verify
Metaproterenol (orciprenaline)
Metaproterenol (generic name: orciprenaline) is a beta2-Adrenergic Agonist drug. It is currently FDA-approved (first approved 1973) for Acute exacerbation of asthma, Asthma, Asthma management.
Metaproterenol, also known as orciprenaline, is a small molecule that acts as a moderately selective β2 adrenergic receptor agonist. It is used in the treatment of asthma, a condition studied in various clinical trials, including those for bronchodilators and exercise capacity in bronchiectasis patients.
At a glance
| Generic name | orciprenaline |
|---|---|
| Drug class | beta2-Adrenergic Agonist |
| Target | Beta-2 adrenergic receptor |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1973 |
Approved indications
- Acute exacerbation of asthma
- Asthma
- Asthma management
- Bronchitis
- Bronchospasm Prevention
- Pulmonary emphysema
Common side effects
Key clinical trials
- Bronchodilators on the Exercise Capacity of Bronchiectasis Patients (NA)
- Beta 2 Adrenergic Stimulation vs Cold Exposure to Activate Human Brown Adipose Tissue (EARLY_PHASE1)
- Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients (NA)
- Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients (PHASE3)
- Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metaproterenol CI brief — competitive landscape report
- Metaproterenol updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Metaproterenol
What is Metaproterenol?
What is Metaproterenol used for?
What is the generic name of Metaproterenol?
What drug class is Metaproterenol in?
When was Metaproterenol approved?
What development phase is Metaproterenol in?
What does Metaproterenol target?
Related
- Drug class: All beta2-Adrenergic Agonist drugs
- Target: All drugs targeting Beta-2 adrenergic receptor
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Acute exacerbation of asthma
- Indication: Drugs for Asthma
- Indication: Drugs for Asthma management
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing